One relatively recent development in treating type 2 diabetes is the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs)
For some, it is approved for weight management, while others use it primarily used to treat type 2 diabetes
In the pancreas GLP-1 receptor agonism boosts insulin secretion in a glucose-dependent mannermeaning insulin rises when blood sugar is high, not indiscriminatelywhile simultaneously suppressing glucagon, the hormone that otherwise pushes the liver to release glucose
Historically, brands focused on HCP education and peer-reviewed evidence to drive prescribing
Compounded medications also offer customizable dosage options, potentially lower costs, and similar benefits when compared to their brand-name counterparts
This is potentially dangerous and almost certainly counterproductive